Key Drivers
- Strong cash runway
- Zero revenue
- High burn/R&D
AIAI Summary
Amylyx is a concentrated, near‑term binary bet—cash into 2028 reduces short‑term solvency risk, but the company's value now hinges on a successful Q3‑2026 LUCIDITY readout plus a broad label and flawless commercialization, so investors should size positions for high downside/dilution risk if the trial, label, or execution falter.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash runway
- •Zero revenue
- •High burn/R&D
AMLX has a strong cash runway (~$227.6M, ~1.8 years of last-year FCF) and minimal debt but no revenue and a large FY loss ($144.7M) driven by heavy R&D/investment and negative operating cash flow.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Short-term pullback
- •Tight resistance band
Over the last month AMLX shows a mild downtrend, slipping from $14.01 to $13.81 with a sharper 5-day pullback from $14.38 to $13.81, facing resistance near $14.9–$15.3 and support around $13.8–$13.9.
5-day pullback from $14.38 to $13.81 indicating accelerated short-term weakness
Sentiment & News
Key News Insights:
- •Phase 3 priority
- •Institutional buys
- •Cash runway
Amylyx is pivoting to avexitide as its sole near-term focus with a Phase 3 readout expected in Q3 2026, institutional buying despite a downgrade, and a cash runway into 2028 to fund the program.
The concentrated bet on avexitide raises upside if LUCIDITY delivers Q3 topline while the reported cash position and investor interest reduce near-term financing risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings